Cumberland Partners Ltd Has $12.29 Million Position in Johnson & Johnson $JNJ

Key Points

• Cumberland Partners Ltd cut its Johnson & Johnson stake by 12.4% in the fourth quarter, selling 8,440 shares and ending with 59,375 shares worth about $12.29 million.
• Johnson & Johnson reported better-than-expected Q1 earnings and revenue, with EPS of $2.70 versus $2.68 expected and sales of $24.06 billion, while also raising its full-year FY2026 EPS guidance to $11.45-$11.65.
• The company recently increased its quarterly dividend to $1.34 per share, and analysts remain broadly positive, with a consensus rating of Moderate Buy and an average price target of $253.04.

Cumberland Partners Ltd reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 12.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,375 shares of the company's stock after selling 8,440 shares during the quarter. Cumberland Partners Ltd's holdings in Johnson & Johnson were worth $12,288,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Plancorp LLC grew its holdings in shares of Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company's stock valued at $3,288,000 after acquiring an additional 45 shares in the last quarter. Baron Silver Stevens Financial Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.8% during the 4th quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company's stock valued at $1,168,000 after acquiring an additional 45 shares in the last quarter. WealthCollab LLC grew its holdings in shares of Johnson & Johnson by 4.7% during the 4th quarter. WealthCollab LLC now owns 1,015 shares of the company's stock valued at $210,000 after acquiring an additional 46 shares in the last quarter. MMA Asset Management LLC grew its holdings in shares of Johnson & Johnson by 1.3% during the 4th quarter. MMA Asset Management LLC now owns 3,600 shares of the company's stock valued at $745,000 after acquiring an additional 46 shares in the last quarter. Finally, Vista Investment Partners II LLC grew its holdings in shares of Johnson & Johnson by 1.2% during the 4th quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company's stock valued at $789,000 after acquiring an additional 47 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $234.67 on Friday. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $564.91 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 2.27 and a beta of 0.27. The firm has a 50-day moving average price of $234.02 and a 200 day moving average price of $223.28.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the prior year, the business posted $2.77 earnings per share. The company's quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.3%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 60.12%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Citigroup upped their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a research report on Tuesday, April 7th. Johnson Rice raised shares of Johnson & Johnson from a "hold" rating to an "outperform" rating in a research report on Wednesday, May 13th. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a research report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.04.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received favorable coverage for its diversified pharma and MedTech businesses, with analysts saying its pipeline progress and stronger 2026 outlook make it better positioned than Pfizer despite patent risks. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
• Positive Sentiment: The company announced China approval for nipocalimab, a regulatory win that expands the drug’s commercial potential and supports sentiment around J&J’s pipeline. Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: J&J also highlighted a next-generation coronary artery disease catheter, reinforcing growth prospects in its MedTech segment and ongoing innovation in interventional medicine. Johnson & Johnson (JNJ) Unveils Next-Gen Catheter for Coronary Artery Disease
• Positive Sentiment: J&J announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s health department, adding another AI-driven MedTech initiative that could strengthen its long-term growth story. Johnson & Johnson Advances Creation of Global Intelligent OR Network
• Neutral Sentiment: J&J was included in broader dividend and blue-chip stock commentary, which may reinforce its reputation as a defensive income stock but does not appear to be a major direct driver. The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You
• Neutral Sentiment: Another article framed J&J as a defensive growth stock, supporting the bull case but offering little new fundamental information. Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Negative Sentiment: ImmunityBio said its ANKTIVA-based bladder cancer data shows a cost advantage versus J&J’s TAR-200, which could raise competitive pressure in an important oncology area. IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J’s TAR-200

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.